Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immucor to acquire BioArray Solutions
The purchase price will be approximately $117 million in cash. The current equity holders of BioArray intend to form a new company prior to closing, to commercialize BioArray
The purchase price will be approximately $117 million in cash. The current equity holders of BioArray intend to form a new company prior to closing, to commercialize BioArray
The study was conducted on 15,730 of the 16,608 postmenopausal women with an intact uterus who had participated in the Womenss Health Initiative (WHI) trial. The average age
It is anticipated that the product branded as ‘Abstral’ will be launched in Sweden in the third quarter of 2008 through Orexo’s joint venture with ProStrakan, the international
The objectives of the studies were to investigate the intravenous and subcutaneous safety assessment of rHuPH20 administered at significantly higher doses to non-human primates than previously examined. The
In a recent study, 49% of UK Members of Parliament of all parties had a favourable view of the pharma industry while 18% were very favourable. Only 16%
The extraordinary price cuts will affect 11 active ingredients in 30 presentations. For the angiotensin II antagonists, the reduction is expected to be around 10%; the top product
The House of Commons health committee report, which was delivered in January, 2008 found that NICE was taking more time for assessing new medicines and in recommending the
Dosing concluded with the successful achievement of the primary endpoint of the study, a prespecified reduction in systemic blood pressure. No volunteer experienced a serious or severe adverse
Pursuant to the agreement, the collaboration will conclude on May 6, 2008. Research efforts under the collaboration have focused on the preclinical development of small molecule and protein
The toxicity screening studies were conducted at Makerere University in Uganda, which is also conducting initial efficacy and toxicity screening for Upstream’s candidates to treat trypanosomiasis, or African